AbbVie Biosimilar Wave: Humira Volume Down 28% in Q4 2025 as Biosimilars Accelerate
By FieldPulse Editorial · February 10, 2026
Tags: biosimilars, compensation, abbvie
AbbVie Humira U.S. net revenues dropped 27.9% in Q4 2025 as biosimilar adalimumab competition continued to accelerate. Skyrizi grew 50% and Rinvoq 39% full-year to offset the decline.
AbbVie reported Q4 2025 earnings showing Humira U.S.
net revenues down 27.9% year-over-year as biosimilar adalimumab competition continued to accelerate.
Full-year 2025 Humira U.S.
revenues declined 57.1% compared to 2024 as high-concentration biosimilars from Amgen, Sandoz, and Boehringer Ingelheim captured an increasing share of new prescriptions.
For the full year, Skyrizi grew approximately 50% and Rinvoq grew 39%, collectively more than offsetting the Humira erosion and driving overall AbbVie immunology revenue growth.
AbbVie reiterated its long-term guidance, with Skyrizi and Rinvoq expected to collectively exceed Humira's peak revenues by 2027.
For reps in the field, the dynamic has shifted from defending Humira to accelerating Skyrizi and Rinvoq uptake in accounts where biosimilar conversions are complete.
Leadership messaging has centered on the transition being largely on track despite steeper-than-expected net price erosion in Humira.